Cerus Corp., of Concord, Calif., is teaming up with several collaborators in its home state, with an eye toward optimizing convalescent plasma therapy for COVID-19 patients. … To help in this regard, the company will work with the California Department of Public Health, University of California, Irvine’s Vaccine Development Research Laboratory, Vitalant Research Institute, California National Primate Research Center and Enable Biosciences. For its part, Cerus already has its Intercept blood system, which works to reduce the risk of transfusion-transmitted infections by inactivating pathogens – including viruses, bacteria and parasites – that may be present in donated blood.
Cerus looks to optimize convalescent plasma therapy
BioWorld, April 1, 2020
April 1, 2020